524 related articles for article (PubMed ID: 17600699)
1. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.
Lin JD; Chao TC; Chen ST; Huang YY; Liou MJ; Hsueh C
Surg Oncol; 2007 Aug; 16(2):107-13. PubMed ID: 17600699
[TBL] [Abstract][Full Text] [Related]
2. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
3. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
4. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.
Yildirim E
J Am Coll Surg; 2005 Mar; 200(3):378-92. PubMed ID: 15737848
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
6. Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of AGES, MACIS, and risk group scores in Mexican population.
Rodríguez-Cuevas S; Labastida-Almendaro S; Cortés-Arroyo H; López-Garza J; Barroso-Bravo S
J Exp Clin Cancer Res; 2002 Mar; 21(1):79-86. PubMed ID: 12071534
[TBL] [Abstract][Full Text] [Related]
7. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
8. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
9. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.
Shaha AR
Laryngoscope; 2004 Mar; 114(3):393-402. PubMed ID: 15091208
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
11. Treatment of locally aggressive well-differentiated thyroid cancer.
Martins AS; Melo GM; Valério JB; Langner E; Lage HT; Tincani AJ
Int Surg; 2001; 86(4):213-9. PubMed ID: 12056464
[TBL] [Abstract][Full Text] [Related]
12. Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer.
Seaberg RM; Eski S; Freeman JL
Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):355-9. PubMed ID: 19380356
[TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.
Malterling RR; Andersson RE; Falkmer S; Falkmer U; Niléhn E; Järhult J
Acta Oncol; 2010 May; 49(4):454-9. PubMed ID: 20092427
[TBL] [Abstract][Full Text] [Related]
14. Conservative management of patients with intrathyroidal well-differentiated follicular thyroid carcinoma.
Saadi H; Kleidermacher P; Esselstyn C
Surgery; 2001 Jul; 130(1):30-5. PubMed ID: 11436009
[TBL] [Abstract][Full Text] [Related]
15. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
16. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
Lin JD; Huang MJ; Hsu BR; Chao TC; Hsueh C; Liu FH; Liou MJ; Weng HF
J Surg Oncol; 2002 May; 80(1):45-51. PubMed ID: 11967907
[TBL] [Abstract][Full Text] [Related]
17. Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer.
Cross S; Wei JP; Kim S; Brams DM
J Surg Oncol; 2006 Dec; 94(8):678-82. PubMed ID: 17131414
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer.
Kushchayeva Y; Duh QY; Kebebew E; D'Avanzo A; Clark OH
Am J Surg; 2008 Apr; 195(4):457-62. PubMed ID: 18070728
[TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
[TBL] [Abstract][Full Text] [Related]
20. Recommendation for subclass evaluation of TNM stage iva papillary thyroid carcinomas: T4aN1b patients are at risk for recurrence and survival.
Wada N; Masudo K; Nakayama H; Suganuma N; Matsuzu K; Hirakawa S; Rino Y; Masuda M; Imada T
Ann Surg Oncol; 2008 May; 15(5):1511-7. PubMed ID: 18299932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
